Characteristics of head to head RCT studies of GLP-1 analogues and Sitagliptin included in the meta-analysis.

I, intervention; C, control; BMI, body mass index; FPG, fasting plasma glucose; EXE, exenatide; SIT, sitagliptin; GLI, glimepiride, QW, every week, QD, every day; NR, not reported.
*the number is obtained by contacting the author;
aCharbonel et al 2013 [32], only data from 1st 12 weeks were used to because after 12 weeks, patients on sitagliptin with an HbA1c ≥7.0% and FFG >6.1 mmol/l had glimepiride added to their treatment regimen for an additional 14 weeks, and patients on liraglutide 1.2 mg/d with an HbA1c ≥7.0% had the liraglutide dose, as per label, titrated up to 1.8 mg/day.
bData of week 26 is obtained from Prateley 2010 [34].